[go: up one dir, main page]

MX2024003249A - Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona. - Google Patents

Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.

Info

Publication number
MX2024003249A
MX2024003249A MX2024003249A MX2024003249A MX2024003249A MX 2024003249 A MX2024003249 A MX 2024003249A MX 2024003249 A MX2024003249 A MX 2024003249A MX 2024003249 A MX2024003249 A MX 2024003249A MX 2024003249 A MX2024003249 A MX 2024003249A
Authority
MX
Mexico
Prior art keywords
fluorobenzofuran
indol
methyl
solid forms
ioxolo
Prior art date
Application number
MX2024003249A
Other languages
English (en)
Inventor
Yamin Zhang
Original Assignee
Actuate Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actuate Therapeutics Inc filed Critical Actuate Therapeutics Inc
Publication of MX2024003249A publication Critical patent/MX2024003249A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)

Abstract

La presente descripción se refiere a formas sólidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5H-[1,3]dioxolo[4,5-f] indol-7-il)pirrol-2,5-diona, procesos para su preparación, composiciones farmacéuticas de las mismas y usos de las mismas en el tratamiento de enfermedades.
MX2024003249A 2017-08-11 2020-02-07 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona. MX2024003249A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762544277P 2017-08-11 2017-08-11

Publications (1)

Publication Number Publication Date
MX2024003249A true MX2024003249A (es) 2024-04-04

Family

ID=63405430

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2020001547A MX2020001547A (es) 2017-08-11 2018-08-10 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
MX2023005875A MX2023005875A (es) 2017-08-11 2020-02-07 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
MX2024003249A MX2024003249A (es) 2017-08-11 2020-02-07 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2020001547A MX2020001547A (es) 2017-08-11 2018-08-10 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
MX2023005875A MX2023005875A (es) 2017-08-11 2020-02-07 Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.

Country Status (16)

Country Link
US (3) US11136334B2 (es)
EP (1) EP3665176B1 (es)
JP (2) JP7424639B2 (es)
KR (3) KR20250070131A (es)
CN (2) CN117362305A (es)
AU (3) AU2018313259B2 (es)
BR (1) BR112020002892A2 (es)
CA (1) CA3072240A1 (es)
DK (1) DK3665176T3 (es)
ES (1) ES2974328T3 (es)
FI (1) FI3665176T3 (es)
IL (2) IL272556B2 (es)
MX (3) MX2020001547A (es)
PL (1) PL3665176T3 (es)
PT (1) PT3665176T (es)
WO (1) WO2019032958A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019079299A1 (en) 2017-10-16 2019-04-25 Actuate Therapeutics Inc. SOLID FORMS OF 3- (5-FLUOROBENZOFURAN-3-YL) -4- (5-METHYL-5H- [1,3] DIOXOLO [4,5-F] INDOL-7-YL) PYRROLE-2,5-DIONE
AU2019271285B2 (en) * 2018-05-17 2024-10-03 Actuate Therapeutics, Inc. Treatment of idiopathic pulmonary fibrosis with glycogen synthase kinase 3 form beta inhibitors
EP4543416A1 (en) 2022-06-27 2025-04-30 Actuate Therapeutics Inc. Oral dosage forms of elraglusib

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2125683B1 (en) 2006-12-19 2013-10-23 The Board of Trustees of the University of Illinois 3-benzofuranyl-4-indolyl-maleimides as potent gsk-3 inhibitors for neurodegenerative disorders
CA2785503A1 (en) 2009-12-23 2011-06-30 Arqule, Inc. Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same

Also Published As

Publication number Publication date
AU2023201059A1 (en) 2023-03-23
WO2019032958A1 (en) 2019-02-14
BR112020002892A2 (pt) 2020-08-04
CN111247153B (zh) 2024-04-02
MX2020001547A (es) 2020-08-03
US20220009939A1 (en) 2022-01-13
CN111247153A (zh) 2020-06-05
IL272556B2 (en) 2025-01-01
US20200223861A1 (en) 2020-07-16
US20250115616A1 (en) 2025-04-10
ES2974328T3 (es) 2024-06-26
KR102700883B1 (ko) 2024-09-02
CN117362305A (zh) 2024-01-09
JP2020530497A (ja) 2020-10-22
KR20250070131A (ko) 2025-05-20
AU2018313259B2 (en) 2022-11-24
MX2023005875A (es) 2023-06-05
KR20200040799A (ko) 2020-04-20
US12145943B2 (en) 2024-11-19
PT3665176T (pt) 2024-03-13
CA3072240A1 (en) 2019-02-14
PL3665176T3 (pl) 2024-06-17
JP7424639B2 (ja) 2024-01-30
IL272556A (en) 2020-03-31
KR20240063198A (ko) 2024-05-09
EP3665176A1 (en) 2020-06-17
IL272556B1 (en) 2024-09-01
IL313800A (en) 2024-08-01
AU2018313259A1 (en) 2020-02-27
JP2023156372A (ja) 2023-10-24
FI3665176T3 (fi) 2024-03-20
US11136334B2 (en) 2021-10-05
AU2023201059B2 (en) 2025-04-03
EP3665176B1 (en) 2024-01-24
DK3665176T3 (da) 2024-03-25
AU2025202936A1 (en) 2025-05-15

Similar Documents

Publication Publication Date Title
CO2021007993A2 (es) Compuestos de 2‐formil‐3‐hidroxifeniloximetilo capaces de modular la hemoglobina
MX385332B (es) Moduladores de ror-gamma.
HN2011002406A (es) 2-acetamido-5-aril-1,2,4-triazolonas sustituidas y su uso
MX389847B (es) Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.
MX383715B (es) Formas sólidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carbonil]amino}acético, composiciones, y usos de las mismas.
MX377340B (es) Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares.
PA8770101A1 (es) Amidas de 4-aril-1,4-dihidro-1, 6-naftiridina sustituidas y su uso
ECSP18060875A (es) Derivados de 8-amino-2-oxo-1,3-diaza-espiro-[4.5]-decano
ECSP18060848A (es) Derivados de 3-((hetero)aril)-alquil-8-amino-2-oxo-1,3-diaza-espiro-[ 4.5]-decano
MX2024003249A (es) Formas solidas de 3-(5-fluorobenzofuran-3-il)-4-(5-metil-5h-[1,3]d ioxolo[4,5-f]indol-7-il)pirrol-2,5-diona.
ECSP18060864A (es) Derivados de 3-(carboximetil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
ECSP18060820A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
JOP20210269A1 (ar) تركيبة دوائية مائية لجسم مضاد ضد-il17a واستخدامها
ECSP18060834A (es) Derivados de 3-((hetero)aril)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano
MX2017000764A (es) Formulacion acuosa que comprende paracetamol e ibuprofeno.
BR112018069682A2 (pt) métodos de tratamento para doenças colestáticas e fibróticas
EP4221704A4 (en) PHARMACEUTICAL FORMULATIONS FOR THE TREATMENT OF KDM1A-MEDIATED DISEASES
NI201900023A (es) 1 - arilnaftiridin-3-carboxamidas 7-sustituidas y su uso
UY37671A (es) N-ariletil-2-aminoquinolin-4-carboxamidas sustituidas y su uso
CL2008002060A1 (es) Compuestos derivados de sulfonamida, inhibidores de la produccion de beta amiloide; metodo de preparacion; composicion farmaceutica; kit farmaceutico; y uso en el tratamiento de enfermedades tales como alzheimer, angiopatia amiloide, sindrome de down, entre otras.
BR112019017314A2 (pt) composições farmacêuticas para terapia de combinação
CO2019002853A2 (es) Composiciones de tesofensina
PL425406A1 (pl) Zastosowanie mikropęcherzyków pochodzących z komórek macierzystych w leczeniu stanu zapalnego mózgu, zwłaszcza wywołanego udarem
AR109630A1 (es) Composiciones farmacéuticas de tesofensina
EA201400492A1 (ru) Фармацевтические композиции, содержащие комбинацию основания абакавира и ламивудина